Long QT syndrome

Children's Miracle Network Hospitals® Announces 11 New National Champions Advocating for Pediatric Healthcare

Retrieved on: 
Tuesday, January 2, 2024
Long, PVL, Walking, Nyla, Children's Specialized Hospital, Family, Hospital, Children's Hospital, Occupational therapy, Arrhythmia, Research, State, PTLS, Hope, Bed rest, NICU, Health, Organic, Eye, Infant, Nationwide Children's Hospital, Cancer, Cerebral palsy, Syndrome, Love, Fertilisation, Doctor of Philosophy, Long QT syndrome, Genetic testing, Children's Miracle Network Hospitals, Safety, Prediabetes, DSM-IV codes, National championship, Life, Health insurance

SALT LAKE CITY, Jan. 2, 2024 /PRNewswire-PRWeb/ -- Children's Miracle Network Hospitals proudly introduces its newest cohort of National Champions, a group of extraordinary ambassadors dedicated to raising awareness about the critical need for charitable donations to support pediatric healthcare. These inspirational children and their families hail from diverse backgrounds and represent various member hospitals across the U.S. Each Champion's unique journey exemplifies the profound impact of donations on their lives, underscoring the urgent need to support Children's Miracle Network Hospitals.

Key Points: 
  • Adeline - Duke Children's Hospital (Age: 8)
    "The stories of our National Champions emphasize the transformative impact of charitable donations on pediatric healthcare," said Aimee Daily, Ph.D., President & CEO, Children's Miracle Network Hospitals.
  • Children's Miracle Network Hospitals, the largest fundraising network for children's hospitals in the U.S. and Canada, partners with leading pediatric healthcare providers to give kids a world of possibilities.
  • "The stories of our National Champions emphasize the transformative impact of charitable donations on pediatric healthcare," said Aimee Daily, Ph.D., President & CEO, Children's Miracle Network Hospitals.
  • National Champions are a group of ambassadors for Children's Miracle Network Hospitals located throughout the U.S. As National Champions, they're key to informing the public that children's hospitals are charities in need of donations.

Public advisory - Unauthorized injectable drug products sold online by Canlab Research may pose serious health risks

Retrieved on: 
Wednesday, December 13, 2023
Sale, Peptide, Infant, Abdominal pain, Headache, Triptorelin, Patient, Oxytocin, Ovulation, Water intoxication, Pharyngitis, Infection, Oxygen, Background, Amniotic fluid, Erectile dysfunction, Lethargy, Pharmacy, Vomiting, Placenta, Osteoporosis, Safety, Fertility, Argyreia nervosa, Asphyxia, Canada Border Services Agency, DIN, Pelvimetry, Uterine rupture, Nursing, Drug identification number, Toxemia, Health, Diarrhea, Bleeding, Health Canada, Nausea, Chronic pain, Plasma protein binding, Fetus, Allergy, Somnolence, Anaphylaxis, Endometriosis, Depression, Hormone, Risk, Constipation, History, Premature, Long QT syndrome, Stroke, Seizure, Pain, Natural product, Drug, Upper respiratory tract infection, NPN, Prostate cancer, Prescription drug, Pituitary gland, Dietary supplement

Health Canada is warning consumers not to buy unauthorized injectable drug products from Canlab Research because they may pose serious health risks.

Key Points: 
  • Health Canada is warning consumers not to buy unauthorized injectable drug products from Canlab Research because they may pose serious health risks.
  • The products are promoted as peptides and are sold online via Canlab Research websites including www.canlabresearch.com and www.canlab.net .
  • Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks.
  • This is not a complete description of all the unauthorized health products advertised and sold on the Canlab Research websites.

MARKETVUE® REPORT: Surgery remains the only option for the ~50% of LQTS patients refractory or intolerant to beta blockers

Retrieved on: 
Tuesday, November 7, 2023
Long QT syndrome, Libido, ICD, Physician, Video-assisted thoracoscopic surgery, REACH, Risk, Perforation, LQTS, Depression, Subcutaneous Implantable Defibrillator (S-ICD), LCSD, Patient, Fatigue, Pharmaceutical industry

NEWTON, Mass., Nov. 7, 2023 /PRNewswire/ -- Long QT syndrome (LQTS) is a rare congenital cardiac arrhythmia characterized by a prolonged recovery in cardiac action potential that can cause deadly arrhythmias.

Key Points: 
  • According to LQTS experts interviewed by REACH , most cases of LQTS, especially LQTS type 1, are well-controlled by the current standard of care—beta blockers—despite less the less-than-ideal side effects they cause (e.g., fatigue, depression, decreased libido).
  • However, for high-risk patients that experience breakthrough events despite maximal tolerated beta blocker treatment, physicians turn to surgical options that include implantable cardioverter-defibrillators (ICDs) or left cardiac sympathetic denervation (LCSD).
  • Additionally, while a large majority of patients are well-managed by beta blockers, up to half of these patients struggle with the side effects and could benefit from a better-tolerated treatment option.
  • A lot of those are my patients with long QT syndrome who have had an ICD since childhood."

Deep Genomics Introduces the Most Advanced AI Foundation Model for RNA Disease Mechanisms and Candidate Therapeutics

Retrieved on: 
Wednesday, September 27, 2023
Technology, Research, Genetics, Biotechnology, Health, Pharmaceutical, Data Management, Science, Artificial Intelligence, Molecular biology, Database, DNA, Genotype, Drug development, Therapy, Classification, SBO, Genomics, Deep learning, MicroRNA, Gene expression, RNA, RBP, Wilson's disease, Manuscript, Protein, Machine learning, Long QT syndrome, ATP7B, Engineering, Drug discovery, Biology, AI, Exon, Gene, Polyadenylation, Vaccine, New York University

Deep Genomics, a leading AI drug development company focused on decoding biology to program life-changing medicines, announced today the release of the manuscript, “An RNA foundation model enables discovery of disease mechanisms and candidate therapeutics” introducing the company’s AI foundation model, BigRNA.

Key Points: 
  • Deep Genomics, a leading AI drug development company focused on decoding biology to program life-changing medicines, announced today the release of the manuscript, “An RNA foundation model enables discovery of disease mechanisms and candidate therapeutics” introducing the company’s AI foundation model, BigRNA.
  • As outlined in the manuscript, BigRNA accurately predicts the tissue-specific regulatory mechanisms of RNA expression and the binding sites of proteins and microRNAs, plus the effects of variants and candidate therapeutics.
  • Deep Genomics has shown that our unique AI foundation model, BigRNA, can utilize DNA sequences to accurately discover the effects of non-coding, missense and synonymous variants on tissue-specific gene regulation, identify new mechanisms of RNA biology, and design RNA therapeutic candidates,” said Brendan Frey, Ph.D., F.R.S.C., founder and chief innovation officer at Deep Genomics.
  • We believe that BigRNA and deep learning systems like it have the potential to transform the field of RNA therapeutics.”
    “Kudos to Brendan and the team at Deep Genomics for their remarkable research on developing the first foundation model for RNA therapeutics.

Cardiac Pacemakers Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Tuesday, December 6, 2022
United Nations, Degenerative disease, Arrhythmia, Aortic valve, LivaNova, St. Jude Medical, Heart, Atrial fibrillation, Disorder, Medtronic, Long QT syndrome, CVD, Research report, Blood, Patient, Hospital, Nissan Micra, Incidence, World Health Organization, TPS, CNT, COVID-19, Ventricular septal defect, AV, Growth, Heart rate, Hypertension, Atrioventricular block, Boston Scientific, Cardiovascular disease, Cook Group, Organization, Medical device, Cordis

The cardiac pacemakers market is expected to grow to $4.91 billion in 2026 at a compound annual growth rate (CAGR) of 3.62%.

Key Points: 
  • The cardiac pacemakers market is expected to grow to $4.91 billion in 2026 at a compound annual growth rate (CAGR) of 3.62%.
  • The cardiac pacemakers market consists of sales of cardiac pacemaker devices by entities (organizations, sole traders, and partnerships) that are used to maintain the rhythm of heartbeats.
  • New innovations are a key trend in the cardiac pacemaker market.Major players are making innovations like leadless cardiac pacemakers to cater to the cardiac pacemaker market in a better way.
  • The cardiac pacemakers market research report is one of a series of new reports that provides cardiac pacemakers market statistics, including cardiac pacemakers industry global market size, regional shares, competitors with a cardiac pacemakers market share, detailed cardiac pacemakers market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac pacemakers industry.

Thryv Therapeutics Inc. announces the appointment of Pharmaceutical Commercialization Expert Melissa Koomey, M.B.A., to its Board of Directors

Retrieved on: 
Tuesday, November 29, 2022
Marketing, Gilead Sciences, Growth, Culture, Arrhythmia, Cancer, Long QT syndrome, Novartis, Therapy, SGK1, Business administration, LQT, Precision medicine, Melissa, Pfizer, Business school, Pharmaceutical industry, Thryv

MONTREAL, Nov. 29, 2022 /PRNewswire/ - Thryv Therapeutics Inc. is pleased to announce the appointment of Melissa Koomey to its Board of Directors.

Key Points: 
  • MONTREAL, Nov. 29, 2022 /PRNewswire/ - Thryv Therapeutics Inc. is pleased to announce the appointment of Melissa Koomey to its Board of Directors.
  • "We are excited to have Melissa join the Thryv Board of Directors at this pivotal time in our story.
  • In addition, Marc-Olivier Sirard will step down from the Board of Directors and transition to a continued role as Board observer.
  • Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.), is a privately owned company based in Montreal, Quebec, Canada.

Thryv Therapeutics Inc. to Participate in 34th Piper Sandler Annual Healthcare Conference and in RBC Capital Markets Healthcare Private Company Virtual Conference

Retrieved on: 
Thursday, November 17, 2022
Therapy, Cancer, Precision medicine, Conference, Long QT syndrome, Atrial fibrillation, LQT, Thryv, SGK1, Pharmaceutical industry, Serum

MONTREAL, Nov. 17, 2022 /PRNewswire/ -Thryv Therapeutics Inc., a biopharmaceutical company focused on a precision medicine approach to treat Long QT Syndromes via SGK1 inhibition and resistant cancers, will participate in a fireside chat and host investor meetings at the upcoming 34th Piper Sandler Annual Healthcare Conference, and will participate in a fireside chat at the upcoming 2022 RBC Capital Markets Healthcare Private Company Conference.

Key Points: 
  • MONTREAL, Nov. 17, 2022 /PRNewswire/ -Thryv Therapeutics Inc., a biopharmaceutical company focused on a precision medicine approach to treat Long QT Syndromes via SGK1 inhibition and resistant cancers, will participate in a fireside chat and host investor meetings at the upcoming 34th Piper Sandler Annual Healthcare Conference, and will participate in a fireside chat at the upcoming 2022 RBC Capital Markets Healthcare Private Company Conference.
  • Mr. Paul F. Truex will provide a full update on Thryv's progress to date with the development of a number of highly potent SGK1 inhibitors for all major forms of Long QT Syndrome, Atrial Fibrillation and resistant cancers.
  • Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.) is a privately owned pharmaceutical company pioneering a precision medicine approach through the inhibition of Serum and Glucocorticoid induced Kinase (SGK1) to treat Long QT Syndrome, Atrial Fibrillation, and resistant and rare cancers.
  • For more information, visit www.thryvtrx.com .

PCA 500-- the world's most efficient and versatile 12-lead ECG, just received FDA clearance for pediatric use

Retrieved on: 
Tuesday, October 4, 2022
LQTS, Hospital, SIDS, Cardiology, Technology, ECG, CEO, EKG, Multimedia, NIH, Long QT syndrome, Digital, FDA, School, PCA, CRO, American Academy, Partnership, Child, Conference, Patient, Sudden death, We Play (EP), Medical device

LOS ANGELES, Oct. 4, 2022 /PRNewswire/ -- QT Medical announces FDA clearance of PCA 500, a resting 12-lead electrocardiogram (ECG or EKG), for use in pediatric patients.

Key Points: 
  • LOS ANGELES, Oct. 4, 2022 /PRNewswire/ -- QT Medical announces FDA clearance of PCA 500, a resting 12-lead electrocardiogram (ECG or EKG), for use in pediatric patients.
  • The development of PCA 500's pre-positioned electrodes and compact recorder was initially funded by NIH for an easy-to-use ECG specifically designed for pediatric use.
  • QT Medical will introduce PCA 500 to the pediatric market at the 2022 American Academy of Pediatrics National Conference.
  • said Dr. Ruey-Kang Chang, CEO of QT Medical, Inc.
    Two new initiatives will be announced at the pediatric market launch of PCA 500.

Thryv Therapeutics Inc. Announces the Appointment of Dr. Debra Odink to President and Dr. Shi Yin Foo to the Board of Directors

Retrieved on: 
Thursday, September 1, 2022
Cardiovascular disease, Research, CEO, Degenerative disease, Anthera Pharmaceuticals, Therapy, Long QT syndrome, Thryv, US FDA, Board, Arrhythmia, Roche, Board of directors, Biotechnology, FDA, Company, Cancer, Genta (company), Drug development, Development, Pharmaceutical industry, QC

LAVAL, QC, Sept. 1, 2022 /PRNewswire/ - Thryv Therapeutics Inc. is pleased to announce the appointment of Dr. Debra Odink to President and Chief Development Officer of the company and the addition of Dr. Shi Yin Foo to its Board of Directors.

Key Points: 
  • LAVAL, QC, Sept. 1, 2022 /PRNewswire/ - Thryv Therapeutics Inc. is pleased to announce the appointment of Dr. Debra Odink to President and Chief Development Officer of the company and the addition of Dr. Shi Yin Foo to its Board of Directors.
  • Dr. Odink started her career at Roche working in process development and quickly transitioned to start-up, venture backed biotechnology companies.
  • Most recently, at SiteOne Therapeutics, Dr. Odink served as Chief Development Officer and advanced their non-opioid pain therapeutic into clinical development.
  • Dr. Foo is the scientific founder and CEO of Arvada Therapeutics, a company working on novel therapeutics in rare arrhythmic diseases.

Find Therapeutics appoints Paul F. Truex as Chairman of the Board

Retrieved on: 
Monday, August 1, 2022
Celebrity board director, Investment, Degenerative disease, CTI, CEO, VP, Admar Gonzaga, Board, Therapy, Find, Leadership, LQT, Director, Long, Ecosystem, Board of directors, Cancer, CDN, Autoimmunity, Long QT syndrome, Growth, Pharmaceutical industry, Management, Milestone

Find Therapeutics was created in 2020 by CTI Life Sciences and launched with investments from CTI Life Sciences, adMare BioInnovations, Domain Therapeutics and Peptimimesis Pharma.

Key Points: 
  • Find Therapeutics was created in 2020 by CTI Life Sciences and launched with investments from CTI Life Sciences, adMare BioInnovations, Domain Therapeutics and Peptimimesis Pharma.
  • Find Therapeutics is happy to announce that Mr. Truex will serve as Chairman of the Board replacing Laurence Rulleau who will remain as a Board Director, representing CTI LSF III.
  • "On behalf of the Board of Directors, it is a pleasure to welcome Paul to our team," said Philippe Douville, Chief Executive Officer of Find Therapeutics.
  • He has actively participated in multiple IPOs including Milestone (Board member), Trius (Board member), Anthera (CEO), Peninsula (CEO), and Versicor (VP).